Drug Price Transparency Act
This bill requires certain manufacturers of drugs that are covered under Medicare medical services to report pricing information to the Centers for Medicare & Medicaid Services. Specifically, manufacturers of such drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.
| Action Date | Type | Text | Source |
|---|---|---|---|
| 2019-05-21 | Committee | Subcommittee Hearings Held. | House committee actions |
| 2019-04-05 | Committee | Referred to the Subcommittee on Health. | House committee actions |
| 2019-04-04 | Committee | Referred to the Subcommittee on Health. | House committee actions |
| 2019-04-04 | IntroReferral | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. | House floor actions |
| 2019-04-04 | IntroReferral | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. | House floor actions |
| 2019-04-04 | IntroReferral | Introduced in House | Library of Congress |